Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007

Japanese Journal of Chemotherapy

Volumn 57, Issue 2, 2009, Pages 91-96

  Fujimura, Shigeru ^a   Gomi, Kazunori ^b   Takane, Hidenari ^a   Nakano, Yoshihisa ^a   Fuse, Katsuhiro ^b   Kikuchi, Toshiaki ^b   Tokue, Yutaka ^c   Watanabe, Akira ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Arbekacin; Drug resistance; Multiple drug resistant Pseudomonas aeruginosa (MDRP); Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; HABEKACIN; IMIPENEM; KANAMYCIN; LINEZOLID; MEROPENEM; METALLOPROTEINASE; RNA 16S; TEICOPLANIN; THIOGLYCOLIC ACID; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; HOSPITAL INFECTION; JAPAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; WOUND INFECTION;

EID: 63649156786     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Shaw K J, Rather P N, Hare R S, Miller G H: Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57:138-63
2. Fujimura S, Tokue Y, Takahashi H, Kobayashi T, Gomi K, Nukiwa T, et al: Novel arbekacin- and amikacin-modifying enzyme of methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 2000; 190: 299-303
3. Kondo S: Structures of enzymatically modified products of arbekacin by methicillin-resistant Staphylococcus aureus. J Antibiotics 1993; 46: 310-5
4. Yokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, et al: Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 2003; 362: 1888-93
5. Japanese source.
6. Li J, Nation R L, Turnidge J D, Milne R W, Coulthard K, Rayner C R, et al: Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601
7. Tateda K, Ishii Y, Matsumoto T, Yamaguchi K: 'Break-point Checkerboard Plate' for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa. Scand J Infect Dis 2006; 38: 268-72
8. Japanese source.
9. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing, Eighteenth informational supplement. M100-S18. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically M7-A7. Clinical and Laboratory Standards, Wayne, PA 2008; 28: 142-3
10. Japanese source.
11. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, et al: PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003; 41: 5407-13
12. Tsakris A, Pournaras S, Woodford N, Palepou M F, Babini G S, Douboyas J, et al: Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38: 1290-2
13. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo J D, et al: Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000; 44: 891-7
14. Bailey M B: The aminoglycoside. Drugs 1981; 22: 321-7
15. Carlier M B, Laurent G, Claes P J, Vanderhaeghe H J, Tulkens P M: Inhibition of lysosomal phospholipases by aminoglycoside antibiotics; in vitro comparative studies. Antimicrob Agents Chemother 1983; 23: 440-9
16. Brion N, Barge J, Godefroy I, Dromer F, Dubois C, Contrepois A, et al: Gentamicin, netilmicin, dibekacin, and arnikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits. Antimicrob Agents Chemother 1984; 25: 168-72
17. Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K: Pharmacokineties-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chernother 2006; 50: 3763-9
18. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K: Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 3754-62
19. Watanabe A, Yanagihara K, Kohno S, Matsushima T, HAP study group: Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan. Intern Med 2008; 47: 245-54
20. Gastmeier P, Sohr D, Geffers C, Behnke M, Ruden H: Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect Control Hosp Epidemiol 2007; 28: 466-72
21. Kumamoto Y, Tsukamoto T, Matsukawa M, Kunishima Y, Hirose T, Shigeta S, et al: Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). III. Secular changes in susceptibility. Jpn J Antibiot 2006; 59: 217-315
22. Saito T, Aoki Y, Ebara K, Hirai S, Kitamura Y, Kasaoka Y, et al: Surgical-site infection surveillance at a small-scale community hospital. J Infect Chemother 2005; 11: 204-6
23. Ohno K, Nakamura T, Azuma T, Yoshida T, Yamada H, Hayashi H, et al: Surveillance of bacteriological examinations at hospitalization in a pediatric surgical ward. J Pediatr Surg 2008; 43:1507-10
24. Japanese source.
25. Japanese source.
26. Japanese source.
27. Japanese source.